CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

June 19, 2023

Study Completion Date

May 31, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Cabazitaxel

20 mg/m2 Q 21 days

DRUG

Carboplatin

AUC 4 Q21 Days x 6 cycles with ADT

DRUG

Abiraterone

1000 mg PO daily

DRUG

Prednisone

5 mg PO daily on chemotherapy completion

Trial Locations (8)

19107

Thomas Jeferson University, Philadelphia

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

70112

Tulane University, New Orleans

85054

Mayo Clinic Arizona, Phoenix

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

02903

Lifespan Cancer Institute, Providence

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT03934840 - CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | Biotech Hunter | Biotech Hunter